TCM
ITOS

Tang Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Tang Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,826,692
Closed -$38.2M – 203
2025
Q2 		$38.2M Buy
3,826,692
+1,137,492
+42% +$9.16M 1.93% 12
2025
Q1 		$16.1M Buy
2,689,200
+2,467,484
+1,113% +$18.1M 0.89% 30
2024
Q4 		$1.7M Sell
221,716
-2,186,084
-91% -$18.8M 0.11% 108
2024
Q3 		$24.6M Buy
+2,407,800
New +$36.7M 1.76% 14
2023
Q2 		– Sell
-216,700
Closed -$2.95M – 105
2023
Q1 		$2.95M Hold
216,700
– – 0.44% 54
2022
Q4 		$4.23M Sell
216,700
-720,800
-77% -$14.1M 0.61% 41
2022
Q3 		$17.9M Hold
937,500
– – 2.19% 15
2022
Q2 		$19.3M Hold
937,500
– – 2.93% 10
2022
Q1 		$30.2M Hold
937,500
– – 6.04% 4
2021
Q4 		$43.6M Buy
937,500
+37,500
+4% +$1.25M 8.78% 5
2021
Q3 		$24.3M Buy
900,000
+680,604
+310% +$17.8M 5.05% 7
2021
Q2 		$5.63M Buy
+219,396
New +$5.23M 1.12% 12

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Tang Capital Management's ITOS Position: Q3 2025 in Review

Tang Capital Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 3,826,692 shares — an estimated $38.2M sold.

Tang Capital Management first reported a position in ITOS in Q2 2021 and held it in 12 quarters. The position peaked at $43.6M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Tang Capital Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tang Capital Management sold 3,826,692 iTeos Therapeutics shares in Q3 2025, an estimated $38.2M.
  • Tang Capital Management first reported a position in iTeos Therapeutics in Q2 2021 and held it in 12 quarters.
  • Tang Capital Management's iTeos Therapeutics position peaked at $43.6M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Tang Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.